



INFORMAZIONI PERSONALI **BEATRICE SILVIA ORENA**

	Sesso	Femmina	Data di Nascita	27/03/1990	Nazione	ITALIA
POSIZIONE RICOPERTA	DIRIGENTE BIOLOGO					
Patente di guida	B					
ALLEGATI	Curriculum+Vitae+BO++luglio2025-compresso.pdf					
Dati personali	Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 'Codice in materia di protezione dei dati personali'.					

Curriculum Vitae



Personal Information

<i>Name</i>	Beatrice Silvia Orena
<i>Adress</i>	Corte Belgioioso 6, 20085, Locate di Triulzi (MI)
<i>Telephone</i>	+39 338 4079809
<i>E-mail</i>	beatricesilvia.orena@gmail.com
<i>Nazionalità</i>	Italian
<i>Date of birth</i>	27/03/1990

Education and Training

06/2024	Certificate as “Consulente tecnico d’ufficio”, Università telematica degli studi IUL, Florence, Italy.
01/2022 – present	AMCLI member. N° 7761
01/11/2019 – 31/10/2023	Specialization School in Microbiology and Virology, University of Milan, Milan, Italy. 70/70 cum laude.
20/03/2018	Member of “Ordine Nazionale dei Biologi (ONB)”. N° AA_080322.
01/11/2014 – 31/10/2017	PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
11/2014 – II° session	Italian Biologist Board Certification.
10/10/2012 – 25/06/2014	Master Degree in "Experimental and Applied Biology" (Curriculum: “Human Biology and Biomedical Sciences”), University of Pavia, Italy. Thesis: “Caratterizzazione del meccanismo di inattivazione di un nuovo farmaco antitubercolare”. Supervisor: Prof. Maria Rosalia Pasca. 110/110 cum laude.
13/10/2009 – 25/10/2012	Bachelor Degree in "Biological Sciences", University of Pavia, Italy. Thesis: “Mycobacterium tuberculosis: un nuovo possibile farmaco nell' era della multiresistenza”. Supervisor: Prof. Maria Rosalia Pasca. 105/110.

Work Experience

16/05/2025-present	Permanent contract as Clinical Microbiologist at Laboratorio di Microbiologia Generale e Microbiologia della Fibrosi Cistica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
16/01/2025-15/05/2025	Fixed-term contract as Clinical Microbiologist at Laboratorio di Microbiologia Generale e Microbiologia della Fibrosi Cistica, Fondazione

	IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
01/03/2024-15/01/2025	VAT number as Clinical Microbiologist at Laboratorio di Microbiologia Generale e Microbiologia della Fibrosi Cistica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
01/02/2021– 29/02/2024	Three-year scholarship at Laboratorio di Microbiologia della Fibrosi Cistica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
18/11/2019– 31/10/2023	Specialization School in Microbiology and Virology, University of Milan, Milan, Italy – Laboratorio di Microbiologia e Microbiologia della Fibrosi Cistica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
14/01/2019 – 25/10/2019	Molecular Biologist at Synlab Italia S.r.l., Castenedolo (BS), Italy.
01/11/2014 – 31/10/2017	PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
09/01/2017 – 27/01/2017	Tutoring activity “Integrated Laboratory of Experimental Biology (Microbiology)”, University of Pavia, Italy.
30/11/2015 – 16/12/2015	Tutoring activity “Integrated Laboratory of Experimental Biology (Microbiology)”, University of Pavia, Italy.
17/07/2013 – 16/07/2014	Tutoring activity "Assistance to students in orientation activities", University of Pavia, Italy.
26/10/2012 – 25/06/2014	Internship for Experimental Thesis for the Master Degree "Human Biology and Biomedic Sciences" at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.
15/04/2012 – 25/10/2012	Internship for Experimental Thesis for the Bachelor Degree "Biological Sciences" at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.

Technical skills and competences

Authorization to work in Biosafety Level 3 (BLS3) laboratory with *M. tuberculosis* and *M. avium* complex.

Microbiological techniques

Liquid and solid media preparation and minimal inhibitory concentration (MIC) determination in *E. coli*, *M. smegmatis* and *M. tuberculosis*; sterilization techniques (autoclaving, filtration, UV); bacterial cultures and stricks (*E. coli*, *M. smegmatis*, *M. tuberculosis*); competent cells preparation and bacterial transformation by electroporation with *E. coli*, *M. smegmatis*, and *M. tuberculosis*.

Application of General Microbiology protocols and Cystic Fibrosis (CF) Microbiology protocols, including microscopic, cultural, serological and molecular biology investigations. MIC determination using automated systems (Microscan WalkAway DxM1096, Microscan autoScan4, Vitek), E-test, Kirby-Bauer (KB) disk diffusion susceptibility test, broth-microdilution plates. Phenotypic synergy tests and immunochromatographic tests for antibiotic resistance profiles. Serotyping of *N. meningitis*, *H. influenzae* and *S. pneumoniae*.

Molecular biology techniques

Digestion of DNA by restriction enzymes; PCR amplification; qualitative and quantitative Real-time PCR (Rotorgene 6000 and Q-series, CFX-Biorad, Light-cycler, Smart-cycler); plasmid DNA extraction and purification; gene cloning; genomic DNA extraction and purification from *M. tuberculosis*; RNA extraction from *M. tuberculosis*; gene inactivation in *M. tuberculosis* by recombineering method.

DNA extraction and molecular investigation on stool, mucus, sputum, bronchoalveolar lavage (BAL), blood, liquor, plasma, urine, swabs samples (manual and semi-automated extraction); use of molecular diagnostic platforms (GeneXpert, Film Array, QiaStat, Sanger Sequencing); molecular characterization of *N. meningitis* and *E. coli* Shiga toxin-producing strains. Sanger sequencing for species-level identification of *M. abscessus complex* (*M. abscessus*, *M. bolletii*, *M. massiliense*), *Burkholderia cepacia complex* and fungi. Molecular characterization of antibiotic resistance determinants (using PCR, RT-PCR and/or Sanger sequencing techniques). Reverse dot blot (for Human Papillomavirus and Cystic Fibrosis).

Biochemistry techniques

Heterologous expression and purification of recombinant proteins in *E. coli*; SDS-PAGE; use of spectrophotometer.

Bioinformatic techniques

Use of websites e software that help the annotation and the exploration of genomic data (ClustalW, Blastn, Blastp); use of Qiagility software for rapid, high-precision automated PCR setup; analysis of Sanger sequencing data.

Informatic Techniques

Microsoft Office TM software (Word TM, Excel TM, PowerPoint TM).

Languages

Italian: Mother tongue

English: B2 (Understanding, speaking, writing)

Courses and Masters

18/03-28/05/2017	VIII° Professional training course “Human nutrition and diet-therapy”. Nutrimedifor, Hotel Double Tree by Hilton Milan, Milan, Italy.
11/2015	Training course “Security in Chemical and Biological laboratories”, University of Pavia.
11/2015	Training course “Security and Health in Workplace”, University of Pavia.
21/05/2015-31/10/2018	Junior Partner of Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM).
10-11-18/02/2015	Course “Learn how to design in Europe”, University of Pavia.
23/11/2013	Short Master Nutrifer in "Diet and Nutrition in Sport", Nutrifer, (Italy). AndreolaCentral Hotel, Milan.
16/11/2013	Short Master Nutrifer in "Diet and Nutrition in Pediatric Age", Nutrifer, (Italy). Andreola Central Hotel, Milan.

Meetings

11-15/04/2025	ESCMID Global 2025, Vienna, Austria.
08-11/09/2024	SIM 2024, Pavia, Italy.
27-30/04/2024	ESCMID Global 2024 (ECCMID 2024), Barcelona, Spain.
23-25/11/2023	XXI Convention of investigators in cystic fibrosis, Verona, Italy.
26/02-01/03/2022	AMCLI 2022 – XLIX National Congress, Rimini, Italy.

9-13/07/2017	FEMS 2017 – 7° Congress of European Microbiologists, Valencia, Spain.
20-23/09/2016	FISV 2016 – XIV Congress, University Sapienza of Rome, Rome.
27-28/06/2016	12 th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
11-12/01/2016	11 th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Moderno, Pavia.
23-26/09/2015	Microbiology 2015 - 31 st Meeting of Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna.
25-26/06/ 2015	Human Gut Microbiome and Diseases Congress, Palazzo delle stelline, Milan (CNR - Istituto di tecnologie biomediche, Segrate, Milano).

Oral Communications

11-15/04/2025	Orena BS , Liporace MF, Maraschini A, Girelli D, Stea L, Pizzotti D, Prati D, Caprioli F, Amoroso C, Callegaro A, Cariani L. Donor-screening process for fecal microbiota transplantation in a hospital of northern Italy. ESCMID Global 2025, Vienna.
20-23/09/2016	Orena BS , Chiarelli LR, Esposito M, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušová K, Bellinzoni M, Manganelli R, Marengo E, Ballell- Pages L, Riccardi G, Pasca MR. “ <i>Multitargeting antitubercular compounds: a new precious tool in multidrug resistance age</i> ”. FISV 2016 – XIV Congress, University Sapienza of Rome, Rome.
27-28/06/2016	Orena BS , Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “ <i>Last update from Pavia</i> ”. 12 th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
11-12/01/2016	Orena BS , Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “ <i>PyrG and Rv0579: two promising drug targets</i> ”. 11th Consortium Meeting, More Medicines for Tuberculosis (MM4TB) Hotel Moderno, Pavia.

Posters to national and international meetings

04-07/06/2025	Orena BS , Girelli D, Liporace MF, Tonelli M, D’Accico M, Teri A, Callegaro A, Blasi FBA, Daccò V, Cariani L. <i>The impact of elexacaftor-tezacaftor-ivacaftor therapy on airway infections in people with Cystic Fibrosis</i> . ECFS 2025, Milan, Italy.
11-15/04/2025	Cariani L, Liporace MF, Orena BS , Girelli D, Teri A, Salari F, Alteri C, Gramegna A, Daccò V, Callegaro A, Blasi FBA. <i>Multi Locus Sequence Typing of Pseudomonas aeruginosa strains isolated from people with cystic fibrosis in Elexacaftor-Tezacaftor-Ivacaftor treatment</i> . ESCMID Global 2025, Vienna.
25-28/03/2025	Orena BS , Tonelli M, Girelli D, Liporace MF, D’Accico M, Teri A, Callegaro A, Blasi F, Daccò V, Cariani L. <i>Impatto della terapia con elexacaftor-tezacaftor-ivacaftor (ETI) sui microrganismi polmonari nei pazienti con Fibrosi Cistica</i> . AMCLI 2025, Rimini, Italy.

- 25-28/03/2025 Cariani L, **Orena BS**, Liporace MF, Maraschini A, Girelli D, Niloofar Hejazifar N, Spolti M, Innocenti D, Alteri C, Caprioli F, Amoroso C, Callegaro A. *Challenging donor screening for fecal microbiota transplantation*. AMCLI 2025, Rimini, Italy.
- 25-28/03/2025 Liporace MF, **Orena BS**, Tonelli M, Teri A, Salari¹, Salvato F, Amato S, Giordano G, Girelli D, Grancini Anna¹, Annapaola Callegaro¹, Cariani Lisa. *Comparison of two rapid Antimicrobial Susceptibility Testing (AST) technologies for Gram-negative Bloodstream Infections (BSIs)*. AMCLI 2025, Rimini, Italy.
- 25-28/03/2025 Teri A, Liporace MF, Muscatello A, Terranova L, Carnevale Schianca M, Salari F, **Orena BS**, Gentiloni Silverj F, Bernazzani M, Biscarini S, Renisi G, Cariani L, Canetta C, Bandera A, Alteri C, Callegaro A. *Transmission cluster of cefiderocol-non-susceptible CRAB in cefiderocol-naïve individuals during a single ward outbreak of carbapenem-resistant Acinetobacter baumannii*. AMCLI 2025, Rimini, Italy.
- 8-11/09/2024 **Orena BS**, Liporace MF, Teri A, Girelli D, Nasta M, Mascia V, Girelli D, Alteri C, Gentiloni Silverj F, Matinato C, Callegaro A, Cariani L. *“Active surveillance of patients colonized with carbapenem-resistant Enterobacterales (CRE): results of combined molecular-culture protocol at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan”*. SIM 2024, Pavia, Italy.
- 8-11/09/2024 Teri A, Liporace MF, Girelli D, D’Accico M, Daprai L, Maraschini A, **Orena BS**, Salari F, Valentino L, Matinato C, Alteri C, Cariani L, Callegaro A. *“Prevalence of colonization with CRE, VRE and ESBL strains over three years: a single center experience”*. SIM 2024, Pavia, Italy.
- 5-8/06/2024 Cariani L, Teri A, Girelli D, **Orena BS**, Liporace MF, Zatelli M, D’accico M, Secchi E, Lorè N, Cirillo D, Blasi F, Daccò V. *“Phenotypic and genotypic characterization of Mycobacterium abscessus complex in Cystic Fibrosis patients”*, ECFS 2024, Glasgow, United Kingdom.
- 25-28/03/2024 L Cariani, L Daprai, D Girelli, A Teri, **BS Orena**, MF Liporace, M Zatelli, M Piccoli, A Bazzucchi, MC Mancuso, G Ardissino. *“Epidemiology of STEC infections: 2023 data of the North Italian HUS Network”*. AMCLI 2024, Rimini (Italy).
- 7-10/06/2023 Cariani L, Alicandro G, Teri A, Girelli D, **Orena BS**, Liporace MF, Zatelli M, Ceriotti F, Blasi F, Daccò V. *“The impact of elexacaftor-tezacaftor-ivacaftor (ETI) therapy on occurrence of bacterial lung infections in CF patients”*. ECFS 2023 – 46th European Cystic Fibrosis Conference, Vienna, Austria.
- 15-18/04/2023 Grancini A, Ungaro R, Maraschini A, Daprai L, Bandera A, Muscatello A, Castelli V, Alagna L, Bolis M, **Orena BS**, Matinato C. *“M. hominis and U. urealyticum disseminated infection after hip replacement and shoulder plate synthesis in immune compromised host: a case report”*. ECCMID 2023
- 24-27/03/2023 A Teri, **BS Orena**, M Zatelli, D Girelli, MF Liporace, G Giordano, A Pirrone, M Gemma, C Carozzi, F Ceriotti, C Matinato, L Cariani. *“Outbreak of Acinetobacter baumannii complex: valutazione del fenotipo di resistenza e caratterizzazione molecolare”*. AMCLI 2023 – L National Congress, Rimini, Italy.
- 24-27/03/2023 L Cariani, G Alicandro, **BS Orena**, D Girelli, A Teri, MF Liporace, M Zatelli, V Daccò. *“L’impatto della terapia ivacaftor/tezacaftor/ellexacaftor sulle colonizzazioni batteriche polmonari nei pazienti affetti da Fibrosi Cistica”*. AMCLI 2023 – L National Congress, Rimini, Italy.
- 26/02-01/03/2022 **Orena BS**, Girelli D, Teri A, Lucente MF, Maraschini A, Bono P, Matinato

- C, Ceriotti F, Cariani L. “*Vaccino a mRNA BNT162b2 in pazienti affetti da fibrosi cistica: valore anticorpale e risposta cellulo-mediata CD4+/CD8+*”. AMCLI 2022 – XLIX National Congress, Rimini, Italy.
- 26/02-01/03/2022 Teri A, **Orena BS**, Girelli D, Giordano G, Liporace MF, Matinato C, Ceriotti F, Cariani L. “*Indagine epidemiologica e caratterizzazione molecolare di isolati clinici di Acinetobacter baumannii complex in pazienti affetti da COVID-19*”. AMCLI 2022 – XLIX National Congress, Rimini, Italy.
- 26/02-01/03/2022 Daprai L, **Orena BS**, Liporace MF, Lucente MF, Piccoli M, Matinato C, Ceriotti F. “*Neisseria meningitidis: la sorveglianza e i dati epidemiologici in Lombardia dal 2007 ad oggi*”. AMCLI 2022 – XLIX National Congress, Rimini, Italy.
- 5-7/11/2018 Mori G, **Orena BS**, Rampelli S, Cultrera I, Rengucci C, DeMaio G, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Gaiarsa S, Tibiletti MG, Calistri D, Albertini A, Ranzani GN, Pasca MR. “*Puzzling out gut microbiota composition in sporadic and hereditary colorectal cancer*”. MicrobiotaMi 2018, Milano, Italy. (Selected for oral presentation).
- 17-20/09/2017 Mori G, **Orena BS**, Rampelli S, Rengucci C, DeMaio G, Armanini F, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Gaiarsa S, Albertini A, Ranzani GN, Segata N, Brigidi P, Calistri D, Pasca MR. “*Role of the gut microbiota in the progression of sporadic colorectal adenoma-carcinoma sequence*”. XXXII Meeting of “Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM)”, Palermo, Italy.
- 17-20/09/2017 Chiarelli LR, **Orena BS**, Mori G, Makarov V, Gosetti F, Manfredi M, Kordulakova J, Guerin M, Mikušová K, Marengo E, Riccardi G, Pasca MR. “*Deciphering the cellular mechanism of action of the antitubercular prodrug TP053*”. XXXII Meeting of “Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM)”, Palermo, Italy.
- 9-13/07/2017 **Orena BS***, Mori G*, Gaiarsa S, Armanini F, Segata N, DeMaio G, Rengucci C, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Albertini A, Ranzani GN, Sasserà D, Calistri D, Pasca MR. “*Study of the gut microbiota in the progression of sporadic colorectal adenoma-carcinoma sequence*”. FEMS, Valencia, Spain. (*Equal contribution).
- 9-13/07/2017 **Orena BS**, Chiarelli LR, Mori G, Makarov V, Gosetti F, Manfredi M, Madaacki J, Kordulakova J, Guerin M, Mikušová K, Marengo E, Riccardi G, Pasca MR. “*Understanding the mechanism of action of the prodrug TP053*”. FEMS, Valencia, Spain.
- 25-30/06/2017 Chiarelli LR, **Orena BS**, Mori G, Makarov V, Gosetti F, Manfredi M, Madaacki J, Kordulakova J, Comino N, Guerin M, Mikušová K, Marengo E, Riccardi G, Pasca MR. “*In search for the active metabolites and the cellular target of the antitubercular prodrug TP053*”. Gordon Research Conference, Lucca, Italy.
- 25-30/06/2017 Chiarelli LR, Esposito M, **Orena BS**, Mori G, Gosetti F, Manfredi M, Ekins S, Marengo E, Ballell L, Mikušová K, Riccardi G, Pasca MR. “*CTP synthetase and panthotenate kinase: two new tools for a multi-targeting strategy against Mycobacterium tuberculosis*”. Gordon Research Conference, Lucca, Italy.
- 17-19/10/16 Mori G, **Orena BS**, Armanini F, Segata N, DeMaio G, Rengucci C, Barbieri G, Albertini A, Ranzani GN, Calistri C, Pasca MR. “*Study of the intestinal microbiome in the progression of sporadic colorectal adenoma-carcinoma sequence*”. 4th World Congress on Targeting Microbiota, Institut Pasteur, Paris.

- 19-23/09/16 Chiarelli LR, Esposito M, **Orena BS**, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušová K, Bellinzoni M, Manganelli R, Marengo E, Ballell- Pages L, Riccardi G, Pasca MR. “*Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs*”. EMBO Conference Tuberculosis 2016, Institut Pasteur, Paris. (**Selected for oral presentation**).
- 12-14/05/16 Esposito M, Chiarelli LR, Mori G, **Orena BS**, Pasca MR, Riccardi G. “*Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs*”. Cortona Procarioti 2016. (**Selected for oral presentation**).
- 23-26/09/2015 Mori G*, **Orena BS***, Chiarelli LR, Esposito M, Anatriello M, Makarov M, Riccardi G, Pasca MR. “*Characterization of the mechanism of resistance to the new antitubercular nitro-thienopyrimidine TP053*”. “Microbiology 2015”, 31st Meeting of Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna. (***Equal contribution**).
- 23-26/09/2015 Chiarelli LR, Esposito M, Mori G, **Orena BS**, Makarov V, Bellinzoni M, Degiacomi G, Boldrin F, Marino LB, Manganelli R, Fondi M, Fani R, Mikusová K, S. de Cavaleiro LP, Cole ST, Riccardi G, Pasca MR. “*Mechanism of action of the new antitubercular thiophenecarboxamide derivatives: a multidisciplinary approach*”. “Microbiology 2015”, 31st Meeting of Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna. (**Selected for oral presentation**).

Award

June 2016: 2° Award for the obtained results from the “Scientific Advisor Committee”. 12th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.

Publications

1. Menendez C, Mori G, Maillot M, Fabing I, Carayon C, **Orena BS**, Pasca MR, Voitenko Z, Lherbet C, Baltas M (2015). Synthesis and evaluation of 2-triazolethanol and a,b-diketotriazoles as Antitubercular Agents. *French-Ukrainian Journal of Chemistry*. 3: 82-96.
2. Laborde J, Deraeve C, Lecoq L, Sournia-Saquet A, Stigliani J-L, **Orena BS**, Mori G, Pratviel G, Bernardes-Génisson V (2016). Synthesis, oxidation potential and anti-mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism. *Chemistry Select*. 1: 172–179.
3. Matviuk T, Madacki J, Mori G, **Orena BS**, Menendez C, Kysil A, André-Barrès C, Rodriguez F, Korduláková J, Mallet-Ladeira S, Voitenko Z, Pasca MR, Lherbet C, Baltas M (2016). Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. *Eur J Med Chem*. 123:462-75.
4. Veau D, Krykun S, Mori G, **Orena BS**, Pasca MR, Frongia C, Lobjois V, Chassaing S, Lherbet C, Baltas M (2016). Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity. *ChemMedChem*. 11:1078-89.
5. Chiarelli LR, Mori G, Esposito M, **Orena BS**, Pasca MR (2016). New and Old Hot Drug Targets in Tuberculosis. *Curr Med Chem*. 23: 3813-3846.

6. Esposito M, Szadocka S, Degiacomi G, **Orena BS**, Mori G, Piano V, Boldrin F, Zemanova J, Huszár S, Barros D, Ekins S, Lelièvre J, Manganelli R, Mattevi A, Pasca MR, Riccardi G, Ballell L, Mikušová K, Chiarelli LR (2017). A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors. *ACS Infect Dis.* 3: 428-437.
7. Oliveira PFM, Guidetti B, Chamayou A, André-Barrès C, Madacki J, Korduláková J, Mori G, **Orena BS**, Chiarelli LR, Pasca MR, Lherbet C, Carayon C, Massou S, Baron M, Baltas M (2017). Mechanochemical synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. *Molecules.* 22 (9).
8. Moukrere BR, **Orena BS**, Mori G, Saffon-Merceron N, Rodriguez F, Lherbet C, Belkheiri N, Amari M, Hoffmann P, Fodili M (2017). Evaluation of heteroatom-rich derivatives as antitubercular agents with InhA inhibition properties. *Med Chem Res.* 1-13.
9. Chiarelli LR*, Mori G*, **Orena BS***, Esposito M, Lane T, de Jesus Lopes Ribeiro AL, Degiacomi G, Zemanová J, Szadocka S, Huszár S, Palčėková Z, Manfredi M, Gosetti F, Lelièvre J, Ballell L, Kazakova E, Makarov V, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, Pasca MR (2018). A multitarget approach to drug discovery inhibiting *Mycobacterium tuberculosis* PyrG and PanK. *Sci Rep.* 8: 3187. (*Equal contribution).
10. Mori G, Rampelli S, **Orena BS**, Rengucci C, DeMaio G, Armanini F, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Gaiarsa S, Albertini A, Ranzani GN, Calistri D, Pasca MR (2018). Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. *Sci Rep.* 8:10329.
11. Mori G, **Orena BS**, Franch C, Mitchenallb LA, Godbole AA, Rodrigues L, Aguilar-Pérezd C, Zemanová J, Huszár S, Forbak M, Laneh TR, Sabbahi M, Debooserej N, Fritaj R, Vandeputtej A, Hoffmannj E, Russok R, Connellk N, Veilleuxk C, Kumarc R, Kumark P, Freundlichk JS, Brodinj P, Aínsad JA, Nagarajac V, Maxwell A, Mikušová K, Pasca MR, Ekins S (2018). The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. *Tuberculosis.* 112: 98-109.
12. Meta E, Brullo C, Tonelli M, Franzblau SG, Wang Y, Ma R, Baojie W, **Orena BS**, Pasca MR, Bruno O (2019). Pyrazole and imidazo[1,2-b]pyrazole derivatives as new potential anti-tuberculosis agents. *Med Chem.* 15:17-27.
13. Mori G, **Orena BS**, Cultrera I, Barbieri G, Albertini AM, Ranzani GN, Tibiletti MG, Pasca MR (2019). Gut microbiota analysis in postoperative Lynch syndrome patients. *Front Microbiol.* 10: 1746.
14. Chiarelli LR, Salina EG, Mori G, Azhikina T, Riabova O, Lepioshkin A, Grigorov A, Forbak M, Madacki J, **Orena BS**, Manfredi M, Gosetti F, Buzzi A, Degiacomi G, Sammartino JC, Marengo E, Korduláková J, Riccardi G, Mikušová K, Makarov V, Pasca MR (2020). New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053. *ACS Infect Dis.* 6(2): 313-323.
15. Mori G*, **Orena BS***, Chiarelli LR, Degiacomi G, Riabova O, Sammartino JC, Makarov V, Riccardi G, Pasca MR (2020). Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. *Front Microbiol.* 11: 292 (*Equal contribution).
16. Cariani L*, **Orena BS***, Ambrogio F, Gambazza S, Maraschini A, Dodaro A, Oggioni M, Orlandi A, Pirrone A, Uceda Renteria, A Bernazzani M, Cantù AP, Ceriotti F, Lunghi G (2020). Time length of negativization and cycle threshold values in 182 healthcare workers with COVID-19 in Milan, Italy: an observational cohort study. *Int J Environ Res Public Health.* 17(15):5313. doi: 10.3390/ijerph17155313. (*Equal contribution).

17. Alicandro G, Daccò V, Cariani L, Contarini M, Morlacchi LC, Rosazza C, Sciarrabba CS, Ferraro F, **Orena BS**, Gramegna A, Blasi F, Colombo C (2022). SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. *J Cyst Fibros*, 21(2):e113-e116. doi: 10.1016/j.jcf.2021.12.011. Epub 2021 Dec 13.
18. Alicandro G, Daccò V, Cariani L, Contarini M, Morlacchi LC, Rosazza C, Sciarrabba CS, Ferraro F, Lanfranchi C, **Orena BS**, Gramegna A, Blasi F, Colombo C (2022). Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over. *J Cyst Fibros*. S1569-1993(22)00041-8. doi: 10.1016/j.jcf.2022.02.009.
19. Alicandro G, **Orena BS**, Rosazza C, Cariani L, Russo M, Zatelli M, Badolato R, Gramegna A, Blasi F, Daccò V (2023). Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis. *Vaccine*. 23;41(28):4114-4120. doi: 10.1016/j.vaccine.2023.05.041.
20. Fox V, Mangioni D, Renica S, Comelli A, Teri A, Zatelli M, **Orena BS**, Scuderi C, Cavallero A, Rossi M, Casana M, Mela L, Bielli A, Scutari R, Morelli P, Cariani L, Casari E, Vismara CS, Matinato C, Callegaro A, Bottazzi B, Cassani B, Perno CF, Gori A, Muscatello A, Bandera A, Alteri C (2024). Genomic characterization of *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* (KPC-Kp) strains circulating in three university hospitals in Northern Italy over three years. *Antimicrob Resist Infect Control*. 13(1):70. doi: 10.1186/s13756-024-01429-x.
21. **Orena BS***, Liporace MF*, Teri A, Girelli D, Salari F, Mutti M, Giordano G, Alteri C, Gentiloni Silverj F, Matinato C, Callegaro A, Cariani L (2024). Active Surveillance of Patients Colonized with CRE: A Single-Center Study Based on a Combined Molecular/Culture Protocol. *Antibiotics*.13(11), 1053; <https://doi.org/10.3390/antibiotics13111053>. (*Equal contribution).
22. Alteri C, Teri A, Liporace MF, Muscatello A, Terranova L, Schianca MC, Salari F, **Orena BS**, Silverj FG, Bernazzani M, Biscarini S, Renisi G, Cariani L, Matinato C, Canetta C, Bandera A, Callegaro A (2024). [Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant *Acinetobacter baumannii* in cefiderocol-naïve individuals](#). *Ann Clin Microbiol Antimicrob*, 23(1):104. doi: 10.1186/s12941-024-00763-7.
23. Lanfranchi C, Alicandro G, Cariani L, **Orena BS**, Gramegna A, Rizza C, Blasi F, Daccò V (2025). Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection. *Lung*, 203(1):24. doi: 10.1007/s00408-024-00781-4.
24. Sciò P, Scoffone VC, Parisi A, Bufano M, Caneva M, Trespidi G, Irudal S, Barbieri G, Cariani L, **Orena BS**, Daccò V, Imperi F, Buroni S, Coluccia A (2025). "Identification of new FtsZ inhibitor by virtual screening, mechanistic insights and SAR analyses". *ACS Inf Dis*.
25. Liporace MF, Salari F, **Orena BS**, Piccoli M, Tomassini E, Vezzosi L, Del Castillo G, Daprai L, Cereda D, Alteri C, Callegaro A. Epidemiology of Bacterial Meningitis in the Lombardy Region, Italy, from 2014 to 2024: An Observational, Retrospective Study. *Microorganisms*. 2025, 13(8):1733. doi: 10.3390/microorganisms13081733.